Evommune

EVMN · NYSE · United States

Share price · EVMN

$6.88-7.34 (-51.62%) 3M

close as of 2026-11-18 · 24h delayed · vol 600K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when EVMN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+15.0%
  2. 28 Oct 2026+22.3%
  3. 16 Oct 2026-12.8%
  4. 1 Oct 2026-12.7%
  5. 9 Sep 2026-17.1%
  6. 29 Jun 2026-40.2%
  7. 23 Jun 2026+7.5%

    Nothing announced by EVMN that day or the session before.

  8. 10 Feb 2026+70.9%
  9. 30 Jan 2026-16.4%
  10. 16 Jan 2026-14.3%

    Nothing announced by EVMN that day or the session before.

Share of unusual movement by asset

For each asset, the share of EVMN's own-move activity since 7 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
EVO756
events and moves
4shown from 8 days
EVO301
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—56%
Other company news (earnings, financing, releases naming no asset)—7%
Sessions with no dated event—37%

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
IRAK4Small molecule
Atopic Dermatitis
Phase 2
IL-18Protein / enzyme therapeutic
Atopic Dermatitis
Phase 2
MRGPRX2Small molecule
MigraineUrticaria
Chronic Inducible Urticaria

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-12-10 · Fiscal period ending 2026-09-30
What to watch
2027 (1)
October 2027 (1)
EVO756Phase 2Migraine
Est. primary completion 2027-10 · NCT07616128 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultEVO756Phase 2b of EVO756 in atopic dermatitis did not meet its primary endpoint
Evommune · Source ↗
29 June 2026Topline resultEVO756Phase 2b of EVO756 in chronic spontaneous urticaria did not meet its primary endpoint
Evommune · Source ↗
10 February 2026Topline resultEVO301Phase 2a proof-of-concept trial of EVO301 in atopic dermatitis met its primary endpoint
Evommune · Source ↗

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$25M$49M+ $121M short-term inv.$31M-$26M operating cash flowreport ↗
View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$26M$61M+ $141M short-term inv.$32M-$20M operating cash flowreport ↗
2026-Q1$0$17M$50M+ $163M short-term inv.$22M-$28M operating cash flowreport ↗
2025-Q3$10M$20M$28M+ $49M short-term inv.$12M-$9.6M operating cash flowreport ↗
2025-Q2$0$20M$62M$14M-$26M operating cash flowreport ↗
2025-Q1$3.0M$14M$5.9M$15M-$24M operating cash flowreport ↗
2024-Q3—$13M$18M$16Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$13M$74M$45M+ $105M short-term inv.$17M-$76M operating cash flowreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$7.0M$64M$16M+ $56M short-term inv.$17M-$58M operating cash flowreport ↗
2023-FY——$29M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($164K), 9 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Pena Luis C. · director, President & CEODisposition to issuer (derivative)796,841——Form 4
2026-11-13Bauer Eugene · director, Chief Medical OfficerDisposition to issuer (derivative)100,000——Form 4
2026-11-13Moss Gregory S. · Chief Business & Legal OfficerDisposition to issuer (derivative)293,496——Form 4
2026-11-13Carver Kyle · Chief Financial OfficerDisposition to issuer (derivative)279,408——Form 4
2026-11-13Patel Jeegar Pravinkumar · Chief Scientific OfficerDisposition to issuer (derivative)179,619——Form 4
2026-11-13Drew Janice Suzann · Chief of Dev. OperationsDisposition to issuer (derivative)231,274——Form 4
2026-11-13MCGRAW BENJAMIN F III · directorDisposition to issuer (derivative)37,960——Form 4
2026-11-13Cohen David E · directorDisposition to issuer (derivative)37,960——Form 4